A drug nearing regulatory approval, daraxonrasib, is the first to substantially extend the lives of patients with pancreatic cancer. It works by targeting a cellular protein that fuels not just nearly all pancreatic tumors, but also many lung and colon cancers. Those three are the leading causes of cancer deaths.
#science #pathology #pharmacetucals #medicine #healthcare #oncology
nytimes.com/2026/05/12/health/…